MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of results of a four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study assessing treatment with XOPENEX HFA(TM) (levalbuterol tartrate) Inhalation A...

Financial Highlights* ...

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of results of a double-blind, placebo-controlled study assessing treatment with the short-acting bronchodilator, XOPENEX(R) brand levalbuterol HCl Inhalation Solution, racemic albutero...

Levalbuterol tartrate (Xopenex hFa) is a [beta.sub.2]-agonist, hydrofluoroalkane inhalation aerosol labeled for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. Levalbuterol is the active R-isomer of albuterol (Proven...

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group. Oryx is a specialty pharmaceutical company that markets branded prescription pharmaceutical products...

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that it has been presented with the Ambassador Richard J. Egan Private Sector Leadership Award by the 495/MetroWest Corridor Partnership. Awarded to those companies that the committee believes contribu...

BIA 2-093, Eslicarbazepine Acetate, has Completed Large-Scale Phase III Clinical Studies ...

AEROCOUNT([R]) Dose Indicator integrated with the Alvesco([R]) (ciclesonide) Inhalation Aerosol for the U.S. Market ...

* Acquisition creates a commercial platform for Sepracor in the Canadian specialty pharmaceutical market ...

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that clinical data for XOPENEX HFA HFA - Haifa, Israel - International Airport (Airport Code)HFA - Handsfree Allowed (digital telephones)HFA - Hard Fibres AssociationHFA - Hardened Flexible ArrayHFA -...

2006 Product Revenues Increased by 51% Over 2005MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the fourth quarter and full year 2006.For the three months ended December 31, 2006, Sepracor's consolidated rev...

* Collaboration is the first partnership for expansion of the LUNESTA([R]) brand eszopiclone franchise outside of U.S. * Eisai to complete development of eszopiclone in Japan and will have exclusive marketing rights to the product for the Japanese market * S...

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that BROVANA([TM]) brand arformoterol tartrate Inhalation Solution is now available by prescription in pharmacies nationwide. BROVANA is a long-term, twice-daily (morning and evening), maintenance...

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that clinical data for XOPENEX HFA HFA - Haifa, Israel - International Airport (Airport Code)HFA - Handsfree Allowed (digital telephones)HFA - Hard Fibres AssociationHFA - Hardened Flexible ArrayHFA -...

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that it has entered into a Settlement and License Agreement with Breath Limited (Breath), an Arrow Group subsidiary, to resolve the patent litigation involving Sepracor's XOPENEX([R])brand levalbu...

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the first quarter of 2007. For the three months ended March 31, 2007, Sepracor's consolidated revenues were approximately $331.4 million, of which revenue...

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced its intention to fully support the Pharmaceutical Research and Manufacturers of America's (PhRMA) updated and enhanced Code on Interactions with Healthcare Professionals (PhRMA Code). The purpose ...

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that clinical data for XOPENEX HFA HFA - Haifa, Israel - International Airport (Airport Code)HFA - Handsfree Allowed (digital telephones)HFA - Hard Fibres AssociationHFA - Hardened Flexible ArrayHFA -...

* Ciclesonide is a corticosteroid with a unique activation mechanism and is a prodrug activated by intracellular esterases following oral or nasal inhalation * In a large-scale Phase II study, ciclesonide delivered in an aerosol nasal formulation utilizing hyd...